The resulting effect deriving from the combination of the catalytic inhibition and the enhancement of the signaling function of IDO1 may strongly depend on the cell type (i.e., tumor and/or immune cell populating the tumor microenvironment). The gene discussed is IDO1; the disease is neoplasm.